Allergy Therapeutics plc (AIM: AGY)

Market Cap	367.77M
Revenue (ttm)	55.20M
Net Income (ttm)	-40.22M
Shares Out	4.78B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	434,860
Average Volume	583,282
Open	7.60
Previous Close	7.60
Day's Range	7.01 - 7.70
52-Week Range	0.07 - 8.00
Beta	1.34
RSI	73.57
Earnings Date	Dec 24, 2024

About Allergy Therapeutics

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to ad...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 612
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: AGY

Financial Performance

In 2024, Allergy Therapeutics's revenue was 55.20 million, a decrease of -7.36% compared to the previous year's 59.59 million. Losses were -40.22 million, -6.63% less than in 2023.